Skip to main content
ARS Home » Northeast Area » Orient Point, New York » Plum Island Animal Disease Center » Foreign Animal Disease Research » Research » Research Project #438734

Research Project: Evaluation of Lyophilization on efficacy of African Swine Fever Vaccine Candidate ASFV-G-delta I177L

Location: Foreign Animal Disease Research

Project Number: 8064-32000-063-024-T
Project Type: Trust Fund Cooperative Agreement

Start Date: Oct 15, 2020
End Date: May 30, 2022

African swine fever virus (ASFV) is a significant threat to agriculture in the United States. There are currently no commercial vaccines available to protect pigs against infection with ASFV and disease can result in devastating losses with up to 100% mortality. Of special concern is the highly pathogenic Georgia isolate, which is currently causing the current outbreaks all across Asia and Eastern Europe. ARS, PIADC has recently discovered several new experimental live-attenuated vaccine candidates, of which ASFV-G-delta I177L is the best candidate. This research project seeks to determine the stability of ASF Vaccine candidate ASFV-G-delta I177L, after lyophilization. Specific objectives include: 1. Test stability of ASFV-G-'I177L to be lyophilized 2. Compare different formulations for freeze drying and stability over time 3. Test the ability of lyophilized ASFV to vaccinate swine against ASFV-Georgia

Several different lyophilization formulations consisting of bovine serum albumin (BSA), l-glutamic acid (L-Glu), polyethylene glycol (PEG), and dextran (DEX) to test ASFV-G-delta I177L for stability after lyophilization will be conducted. We will test several different formulations and after lyophilization we will test for infectivity of the virus, by viral titrations. Successful formulations will then be tested for storage at different temperatures for set periods of time between 1 week and six months. The most stable formulation of ASFV-G-delta I177L will be reconstituted and tested for vaccine efficacy in pigs against ASFV-Georgia.